Mallinckrodt Pharmaceuticals A.I CyberSecurity Scoring
28/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
No incidents recorded for Mallinckrodt Pharmaceuticals in 2026.
The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Latest updates, reports, and threat intel affecting the global network.
A Delaware federal jury awarded Mallinckrodt Pharmaceuticals almost $9.5 million on Friday, finding that French industrial gas company...
Endo's shareholders will receive $80 million in cash and own 49.9% of the combined company for a pro forma enterprise deal value of $6.7 billion.
Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from bankruptcy...
Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to...
Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and US opioid litigation, will merge in a deal valued at nearly $7 billion.
Mallinckrodt Pharmaceuticals and Endo have agreed to combine in a nearly $7bn deal after the pair emerged from bankruptcy processes linked to liabilities over...
Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the matter told...
PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has...
Drugmaker Mallinckrodt on Tuesday won court approval for a bankruptcy plan that cuts $1 billion from what it must pay opioid crisis victims,...
docker-socket-proxy fails to properly gate read endpoints in the /containers Docker API namespace when the CONTAINERS environment variable is set. Attackers can use GET requests to /containers/{id}/archive, /containers/{id}/export, /containers/{id}/logs, and /containers/{id}/top to read arbitrary files and download entire container filesystems as tar archives.
A vulnerability has been found in Systerel S2OPC up to 1.7.3. Impacted is the function SOPC_NodeMgtHelperInternal_AddVariableNodeAttributes of the file src/ClientServer/address_space/internal/sopc_node_mgt_helper_internal.c of the component AddNodes Service. The manipulation of the argument UserAccessLevel leads to out-of-bounds read. It is possible to initiate the attack remotely. A high degree of complexity is needed for the attack. The exploitability is considered difficult. The exploit has been disclosed to the public and may be used. The identifier of the patch is aafbd37d381b618312ebdf5ddf57027f62c14fdd. It is suggested to install a patch to address this issue.
The Infineon Airoc Wi-Fi driver's transmit callback airoc_mgmt_send() in drivers/wifi/infineon/airoc_wifi.c allocates a net_buf from the fixed airoc_pool for every outbound packet. When whd_network_send_ethernet_data() returns a synchronous failure, the underlying WHD library does not take ownership of the buffer, but the pre-fix driver returned -EIO without releasing it. Each failed transmit therefore permanently leaks one buffer from the pool. airoc_pool is small and fixed (AIROC_WIFI_TX_PACKET_POOL_COUNT + AIROC_WIFI_RX_PACKET_POOL_COUNT, default 20 buffers) and is shared by WHD's whd_host_buffer_get callback for both transmit and receive. Once enough send failures have leaked the pool dry, airoc_wifi_host_buffer_get() returns WHD_BUFFER_ALLOC_FAIL for all subsequent allocations, so both transmit and the WHD-driven receive path fail and Wi-Fi connectivity is lost until the device is rebooted. The leak occurs only on the transmit error path. A Wi-Fi-adjacent attacker can influence the conditions that cause synchronous send failures (for example by deauthenticating/disassociating the station while the local stack continues to attempt transmits), and ordinary transient failures over the device's lifetime accumulate toward the same state. Reliable on-demand triggering is of high complexity and the impact is availability-only, but the resulting denial of service is permanent and non-recoverable without a reboot. The fix releases the buffer with airoc_wifi_buffer_release() on the failure branch, returning it to the pool. The commit also removes a redundant k_sem_give() in airoc_mgmt_disconnect(); because data->sema_common is a binary semaphore (limit 1) the duplicate give merely saturated at 1 and had no security impact.
In the Linux kernel, the following vulnerability has been resolved: gpio: pca953x: fix pca953x_irq_bus_sync_unlock regmap lock Locking is disabled in the regmap config as this driver uses its own lock. This means that all calls to regmap functions (read or write) must hold the i2c_lock. The function pca953x_irq_bus_sync_unlock() did not do this, and it was therefore possible that multiple threads could cause an incorrect register to be read/written. A previous patch partly fixed this, but only protected the write to the interrupt mask register, and not the read from the direction register.
In the Linux kernel, the following vulnerability has been resolved: drm/amd/display: Check for tg ops in dce110_set_avmute Some older DCE timing generators do not implement is_tg_enabled in their ops table. Calling it unconditionally when waiting for AV mute frames causes a NULL pointer dereference on Southern Islands dGPUs when turning the display off over HDMI. Check that tg and the required ops exist before waiting for frames. (cherry picked from commit 2686a0c0aaa07bec2e24131835cf27b5fd4935a5)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.